✦ LIBER ✦

24 Outcome in metastatic NSCLC without EGFR and KRAS mutation treated with second line erlotinib

✍ Scribed by Dua, D.; Montes, A.; Warner, M.; Spicer, J.; Lal, R.

Book ID: 122222904
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 48 KB
Volume: 83
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(14)70025-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-186 Mutations in EGFR, HER2, KRAS and

O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib

✍ Eberhard, D.; Johnson, B.; Goddard, A.; Herbst, R.; Janne, P.; Johnson, D.; Klei 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 185 KB

The Impact of EGFR T790M Mutations and B

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

✍ Costa, C.; Molina, M. A.; Drozdowskyj, A.; Gimenez-Capitan, A.; Bertran-Alamillo 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 651 KB

6005 PIK3CA, BRAF and KRAS mutations and

6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium

✍ Tejpar, S.; De Roock, W. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

471 KRAS, BRAF and PIK3Ca Mutations as P

471 KRAS, BRAF and PIK3Ca Mutations as Predictors of Outcome From Maintenance Therapy with Bevacizumab with or Without Erlotinib After First Line Combination Therapy for Metastatic Colorectal Cancer: Results of the Phase III ACT Trial NCT00598156 Translational Study

✍ Spindler, K.G.; dePont Christensen, R.; Andersen, R.F.; Pallisgaard, N.; Johnson 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

9017 POSTER DISCUSSION Initial Detection

9017 POSTER DISCUSSION Initial Detection of the Double Epidermal Growth Factor Receptor (EGFR) Mutation (L858R or Deletion in Exon 19 [del 19] Plus T790M) in Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Brain Metastases (mets) and the Influence of First-Line Chemotherapy on Outcome to Erlotinib

✍ Rolfo, C.; Moran, T.; Sanchez, J.; Molina-Vila, M.; Bertran-Alamilllo, J.; Camps 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB